It is increasingly appreciated that epigenetic alterations, which occur both in tumor cells and in immune cells within the TME (such as CD11b+ myeloid cells, CD4+ and CD8+ lymphoid cells), further increase the complexity within tumor tissue and represent major determinants of cancer cell growth, immune evasion and drug resistance (1, 2). Here, ITGAM is linked to neoplasm.